Biotechnology Fund Class Fund Quote

RYOAX Fund  USD 64.45  10.45  19.35%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 24

 
High
 
Low
Low
Biotechnology Fund is trading at 64.45 as of the 16th of December 2024; that is 19.35 percent increase since the beginning of the trading day. The fund's open price was 54.0. Biotechnology Fund has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 16th of November 2024 and ending today, the 16th of December 2024. Click here to learn more.
Under normal circumstances, the fund invests substantially all of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. More on Biotechnology Fund Class

Moving together with Biotechnology Mutual Fund

  0.63RYBCX Basic MaterialsPairCorr

Biotechnology Mutual Fund Highlights

Fund ConcentrationRydex Funds, Large Funds, Health Funds, Health, Rydex Funds, Large, Health (View all Sectors)
Update Date31st of December 2024
Expense Ratio Date19th of August 2022
Fiscal Year EndMarch
Biotechnology Fund Class [RYOAX] is traded in USA and was established 16th of December 2024. Biotechnology Fund is listed under Rydex Funds category by Fama And French industry classification. The fund is listed under Health category and is part of Rydex Funds family. This fund at this time has accumulated 117.21 M in assets with no minimum investment requirementsBiotechnology Fund Class is currently producing year-to-date (YTD) return of 2.62%, while the total return for the last 3 years was -1.38%.
Check Biotechnology Fund Probability Of Bankruptcy

Instrument Allocation

Sector Allocation

Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Biotechnology Mutual Fund. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Biotechnology Mutual Fund, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as Biotechnology Fund Class Mutual Fund, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.

Top Biotechnology Fund Class Mutual Fund Constituents

HZNPHorizon Pharma PLCStockHealth Care
VRTXVertex PharmaceuticalsStockHealth Care
SGENSeagen IncStockHealth Care
REGNRegeneron PharmaceuticalsStockHealth Care
MRNAModernaStockHealth Care
INCYIncyteStockHealth Care
ILMNIlluminaStockHealth Care
ABBVAbbVie IncStockHealth Care
More Details

Biotechnology Fund Class Risk Profiles

Biotechnology Fund Against Markets

Other Information on Investing in Biotechnology Mutual Fund

Biotechnology Fund financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Fund security.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine